[
  {
    "ts": "2025-09-27T04:59:23+00:00",
    "headline": "Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions",
    "summary": "Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after the company revealed updated clinical trial findings for its medication povorcitinib. The company evaluated povorcitinib in patients with moderate-to-severe hidradenitis suppurativa in its pivotal Phase 3 STOP-HS1/HS2 […]",
    "url": "https://finance.yahoo.com/news/incyte-incy-advances-clinical-trials-045923585.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "7ceefff4-3b2c-3d0d-87bd-bd2777026f12",
      "content": {
        "id": "7ceefff4-3b2c-3d0d-87bd-bd2777026f12",
        "contentType": "STORY",
        "title": "Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions",
        "description": "",
        "summary": "Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after the company revealed updated clinical trial findings for its medication povorcitinib. The company evaluated povorcitinib in patients with moderate-to-severe hidradenitis suppurativa in its pivotal Phase 3 STOP-HS1/HS2 […]",
        "pubDate": "2025-09-27T04:59:23Z",
        "displayTime": "2025-09-27T04:59:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4d11e3fba94461c20ce4eca58ae1ba5f",
          "originalWidth": 612,
          "originalHeight": 409,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cFOlf0F_1l12fITvvtj8zA--~B/aD00MDk7dz02MTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4d11e3fba94461c20ce4eca58ae1ba5f.cf.webp",
              "width": 612,
              "height": 409,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sGtdNxF47lsFByzXp6rdXA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4d11e3fba94461c20ce4eca58ae1ba5f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-incy-advances-clinical-trials-045923585.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-incy-advances-clinical-trials-045923585.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRM"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]